| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 22.044 | 24.959 | 3.131 | 4.015 | 16.783 | 24.169 | 20.818 | 47.870 |
| Total Income - EUR | - | - | 22.044 | 24.959 | 3.131 | 4.015 | 16.783 | 24.923 | 20.818 | 47.870 |
| Total Expenses - EUR | - | - | 11.980 | 30.133 | 3.527 | 7.717 | 3.654 | 11.956 | 20.201 | 50.408 |
| Gross Profit/Loss - EUR | - | - | 10.064 | -5.174 | -395 | -3.701 | 13.129 | 12.967 | 618 | -2.538 |
| Net Profit/Loss - EUR | - | - | 9.722 | -5.423 | -441 | -3.810 | 12.635 | 12.332 | 534 | -2.538 |
| Employees | - | - | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
Check the financial reports for the company - Iomatib Trans Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | 10.977 | 4.307 | 3.897 | 1.020 | 16.204 | 34.576 | 29.150 | 11.220 |
| Inventories | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | 2.918 | 418 | 1.268 | 928 | 9.867 | 11.458 | 11.189 | 10.845 |
| Cash | - | - | 8.059 | 3.890 | 2.629 | 92 | 6.338 | 23.118 | 17.961 | 375 |
| Shareholders Funds | - | - | 9.765 | 4.163 | 3.641 | -238 | 12.402 | 24.772 | 25.231 | 4.861 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 1.211 | 145 | 257 | 1.258 | 3.802 | 9.804 | 3.919 | 6.359 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4941 - 4941" | |||||||||
| CAEN Financial Year |
4941
|
|||||||||
Comments - Iomatib Trans Srl